Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Mesothelioma 53Advanced Solid Tumors 53Solid Tumor 51Advanced Solid Tumor 41Mesothelioma, Malignant 38Solid Tumors 35Unspecified Adult Solid Tumor, Protocol Specific 27Carcinoma, Non-Small-Cell Lung 25Retinoblastoma 14Melanoma 14Esophageal Neoplasms 14Solid Tumor, Adult 13Sarcoma 12Ovarian Neoplasms 12Lung Neoplasms 11Carcinoma, Renal Cell 11Uterine Cervical Neoplasms 10Small Cell Lung Carcinoma 10Stomach Neoplasms 9Breast Neoplasms 9Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Advanced Solid Tumours 7Neoplasms 6Urinary Bladder Neoplasms 5Thyroid Neoplasms 5Solitary Fibrous Tumor, Pleural 5Malignant Solid Tumor 5

Interventions

defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Mesothelial × Other solid neoplasm × Clear all
NCT02004028 2024-02-20

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Verastem, Inc.

Phase 2 Terminated
35 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Adenoma, Mesothelioma, Neoplasms, Mesothelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡